UK-based Oxford BioMedica has signed a new collaboration and licence agreement with Bioverativ for the development and manufacture of lentiviral vectors to treat haemophilia.

The agreement will see an upfront payment of $5m by Bioverativ to Oxford BioMedica, which is also eligible for an additional $100m in different milestone-based payments.

Oxford BioMedica will also receive net sales royalties on Bioverativ’s lentiviral vector haemophilia products.

Oxford BioMedica CEO John Dawson said: “Bioverativ’s investment in haemophilia gene therapy underlines the potential of lentiviral vectors for use for in-vivo gene therapy.

“This new deal, potentially worth in excess of $100m, demonstrates Oxford BioMedica’s strategy of building multiple partnerships with leaders in their therapeutic categories and will support the group’s continued growth.”

“Bioverativ’s investment in haemophilia gene therapy underlines the potential of lentiviral vectors for use for in vivo gene therapy.”

The agreement also involves a licence to leverage Oxford BioMedica’s LentiVector Enabled technology, as well as access to the firm’s industrial-scale manufacturing technology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Tick here to opt out of curated industry news, reports, and event updates from Pharmaceutical Technology.

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Designed as an advanced lentiviral-based gene delivery system, the LentiVector platform has applications in various therapeutic areas. It can genetically modify dividing and non-dividing cells, and insert genes into non-dividing cells.

The platform also acts as a research tool with uses in stem cell manipulation, transgenesis, somatic disease models, target validation and gene discovery.

Bioverativ will sponsor the activities associated with the process development and scale-up of its lentiviral vector haemophilia products at Oxford BioMedica.

In addition, the agreement includes an option to negotiate a clinical supply agreement for GMP manufacturing of these products at the company.